BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
SPARC to receive 55% equity in Tiller Therapeutics
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Subscribe To Our Newsletter & Stay Updated
